EUVIMEDEUVIMED entdecken
EUVIMED · CrossrefZeitschrift

International Journal of Clinical Oncology

ISSN 1341-9625 · Springer Science and Business Media LLC

Neueste Artikel

  1. Risk factors for pneumonitis development in patients with platinum-refractory head and neck cancer treated with salvage-line chemotherapy after nivolumab failure

    Ari Nishimura, Takane Watanabe, Hiroki Oka, Kengo Nagashima, Hideaki Nishi, Yoshihiko Kumai, Hiroaki Iijima, Kenji Okami, Yasushi Shimizu, Satoshi Kano, Kazue Ito, Tomoko Yamazaki, Hideaki Takahashi, Nobuhiko Oridate, Tomoya Yokota, Taiji Koyama, Naomi Kiyota, Yasuyoshi Sato, Shunji Takahashi, Kyoko Kato, Shigenori Kadowaki, Yoshitaka Honma

    Erschienen: 2026-11-10DOI: 10.1007/s10147-026-03231-8

  2. Prognostic impact of primary Gleason pattern 5 in patients with low-volume metastatic hormone-sensitive prostate cancer treated with upfront ARPI-based doublet therapy: a real-world multicenter international collaborative study

    Yasutaka Yamada, Kodai Sato, Hao-Lun Luo, Hung-Jen Wang, Hui-Ying Liu, Yin-Lun Chang, Yu Li Su, Chun-Te Wu, Kai-Jie Yu, Po-Hung Lin, Chung-Yi Liu, Dong-Ru Ho, Yun-Ching Huang, Takuya Tsujino, Shinpei Saito, Ryoichi Maenosono, Kazuki Nishimura, Tatsuo Fukushima, Ko Nakamura, Satoshi Yamamoto, Takayuki Arai, Hiroaki Sato, Kosuke Higuchi, Akira Kurozumi, Akinori Takei, Manato Kanesaka, Keisuke Ando, Koichiro Kurokawa, Sanji Kanaoka, Nobushige Takeshita, Kei Yoneda, Daichi Hino, Takaaki Tamura, Tomokazu Sazuka, Yusuke Imamura, Kazuo Mikami, Kazuyoshi Nakamura, Satoshi Fukasawa, Yukio Naya, Maki Nagata

    Erschienen: 2026-11-06DOI: 10.1007/s10147-026-03240-7

  3. Correction: Optimal adjuvant strategy in intermediate-risk cervical cancer: a systematic review and meta-analysis

    Akira Yokoi, Hiroko Machida, Mika Okazawa-Sakai, Koji Nishino, Hanae Sekine, Mizue Itoi, Takumi Mitamura, Fumiaki Isohashi, Keisuke Tsuchida, Haruya Saji, Satoe Fujiwara, Noriko Ii, Miho Watanabe, Tadaaki Nishikawa, Satoshi Nakagawa, Michiko Kodama, Shinya Sato, Kazuhiro Takehara, Tohru Morisada, Shin-ei Noda, Munetaka Takekuma, Hiroaki Kajiyama, Hideki Tokunaga, Tsukasa Baba, Yoichi Kobayashi, Aikou Okamoto

    Erschienen: 2026-10-29DOI: 10.1007/s10147-026-03225-6

  4. Sex differences in the prognostic value of body mass index after curative nephrectomy for high-risk renal cell carcinoma: a multicenter cohort study

    Shigeki Koterazawa, Takayuki Sumiyoshi, Noboru Shibasaki, Toshinari Yamasaki, Noriyuki Ito, Takehiko Segawa, Koji Inoue, Sojun Kanamaru, Toru Yoshida, Kazutoshi Okubo, Yoshio Sugino, Toru Kanno, Norihiko Masuda, Masakatsu Ueda, Shuhei Koike, Akihiro Hoshiyama, Hiromasa Araki, Ken Maekawa, Takaaki Takuma, Takehiro Yamane, Yuki Kita, Takayuki Goto, Takashi Kobayashi, Kimihiko Masui

    Erschienen: 2026-10DOI: 10.1007/s10147-026-03134-8

  5. Optimal adjuvant strategy in intermediate-risk cervical cancer: a systematic review and meta-analysis

    Akira Yokoi, Hiroko Machida, Mika Okazawa-Sakai, Koji Nishino, Hanae Sekine, Mizue Itoi, Takumi Mitamura, Fumiaki Isohashi, Keisuke Tsuchida, Haruya Saji, Satoe Fujiwara, Noriko Ii, Miho Watanabe, Tadaaki Nishikawa, Satoshi Nakagawa, Michiko Kodama, Shinya Sato, Kazuhiro Takehara, Tohru Morisada, Shin-ei Noda, Munetaka Takekuma, Hiroaki Kajiyama, Hideki Tokunaga, Tsukasa Baba, Yoichi Kobayashi, Aikou Okamoto

    Erschienen: 2026-06DOI: 10.1007/s10147-026-03028-9

Jahrgänge

2026 · 2452025 · 2722024 · 2162023 · 1722022 · 2192021 · 2532020 · 2562019 · 1942018 · 1532017 · 1462016 · 1672015 · 1712014 · 1632013 · 1652012 · 972011 · 1292010 · 1192009 · 1072008 · 1072007 · 872006 · 842005 · 722004 · 1002003 · 682002 · 602001 · 542000 · 721999 · 801998 · 741997 · 481996 · 37

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.